TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06217822: A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant

Sponsor: Bayer · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 198 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$7,005,768

Rescue Site Savings

+$4,618,152

Unlock Full NCT06217822 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06217822 Rescue Dossier →